Ultimo aggiornamento: agosto 17, 2026
Cell Therapy Products
Alofisel
TIGENIX
An allogeneic stem cell therapy to treat complex perianal fistulas in patients with Crohn’s disease. Received EU marketing authorisation in March 2018.
Cartistem
MEDIPOST
A cellular therapeutic agent containing allogeneic human umbilical cord blood-derived mesenchymal stem cells, indicated for the treatment of knee cartilage defects such as traumatic articular cartilage, degenerative arthritis and rheumatoid arthritis. Approved for marketing by South Korea’s Ministry of Food and Drug Safety in January 2012.
Cellgram-AMI
FCB PHARMICELL
An autologous intracoronary bone marrow-derived mesenchymal stem cell injection for the treatment acute myocardial infarction. Approved for marketing by South Korea’s Food and Drug Administration in July 2011.
Cupistem
ANTEROGEN
An autologous adipose derived mesenchymal stem cell treatment to reduce inflammation and regenerate damage joint tissues, indicated for the treatment of Crohn’s fistula. Approved for marketing by South Korea’s Food and Drug Administration in July 2012.
CureSkin
S. BIOMEDICS
An autologous dermal fibroblast cell-based therapy approved in S. Corea dentro 2010 for the treatment of depressed acne scars.
Holoclar
CHIESI FARMACEUTICI
Holoclar is a cell therapy based on autologous cultures of limbal stem cells. It regenerates a functional corneal epithelium allowing recovery of visual acuity. Holoclar is indicated for the treatment of moderate to severe limbal stem cell deficiency due to ocular burns. Granted conditional marketing authorization by the European Commission in February 2015.
Kaloderm
TEGO SCIENCES
An allogeneic cell therapy for deep second degree burns and diabetic foot ulcers. Approvato a S. Korea for burns in 2005 and diabetic foot ulcers in 2010.
KeraHeal
BIOSOLUTIONS
An autologous keratinocyte based cell therapy for the treatment of 2nd degree burns. Approvato a S. Corea dentro 2006.
KeraHeal-Allo
BIOSOLUTIONS
A hydrogel-type allogeneic keratinocyte therapy product for the treatment of second-degree burns. Approvato a S. Corea dentro 2015.
LaViv (Azficel-T)
FIBROCELL TECHNOLOGIES
LaViv is an autologous fibroblast-based cell therapy. Approvato dagli Stati Uniti. FDA in January 2011 for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.
Neuronata-r
CORESTEM
An autologous bone marrow mesenchymal stem cell therapy approved in S. Corea dentro 2014 for the treatment of ALS.
Queencell
ANTEROGEN
An autologous mesenchymal stem cell for the treatment of connective tissue disorders. Approvato a S. Corea dentro 2010.
Rosmir
TEGO SCIENCE
Autologous cell therapy approved in S. Corea dentro 2018 for the treatment of under eye wrinkles.
Spherox (formerly Chrondosphere)
CO.DON AG
A product containing spheroids of human autologous chondrocytes for use in cartilage defects. Marketed in Europe as of 2017; marketed in Germany since 2007.
Stemirac
NIPRO CORP
A mesenchymal stem cell therapy approved in Japan in December 2018 for the treatment of spinal cord injury.
Stempeucel
STEMPEUTICS RESEARCH PVT
An ex-vivo cultured adult allogeneic mesenchymal stromal cell therapy for the treatment of Critical Limb Ischemia. Conditionally approved in India in 2017.
TEMCELL
JCR PHARMACEUTICALS CO LTD, LICENSEE OF MESOBLAST LTD
TEMCELL is an allogeneic mesenchymal stem cell product indicated for the treatment of acute radiation injury, broncopneumopatia cronica ostruttiva, La malattia di Crohn, acute graft-versus-host disease, Type I diabetes and myocardial infarction. Approved by the Japanese Ministry of Health, Labour and Welfare for acute graft-versus-host disease in October 2015 and conditionally approved in Canada & Nuova Zelanda
Revisione scientifica del caso
Ti piacerebbe capire se i programmi clinici sono attuali, recenti sviluppi della ricerca, o potrebbero esserlo gli approcci emergenti rilevante per la tua situazione individuale?
Condividi la tua domanda con il nostro team di ricerca scientifica e ricevi informazioni focalizzate sulle aree di ricerca attuale che potrebbero essere pertinente al tuo caso.
- Revisione delle informazioni fornite
- Informazioni rilevanti sulla ricerca e sul programma clinico
- Una risposta chiara focalizzata sulla tua situazione
Nessun obbligo. La tua domanda verrà esaminata in modo confidenziale.
Solo informazioni didattiche e di ricerca. Questo servizio no costituiscono un parere medico, diagnosi, prescrizione, o uno personalizzato raccomandazione terapeutica.
